Conferences & Events
Filter News
Found 120,956 articles
-
Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as Late-Breaker at 2024 APASL Global Liver Meeting
3/28/2024
Virion Therapeutics, LLC announced promising safety results from the first-ever human data from its novel, first-in-class, checkpoint modifier immunotherapy, VRON-0200, for HBV functional cure, presented by Professor Grace Wong, M.D., from the Chinese University of Hong Kong, as a late breaker oral presentation at the 33rd Annual Meeting of APASL in Kyoto, Japan.
-
Vicore Announces Presentations at the 2024 American Thoracic Society International Conference
3/28/2024
Vicore Pharma Holding AB announced multiple presentations at the 2024 American Thoracic Society International Conference, including an oral late-breaking presentation of the final Phase 2a AIR data of buloxibutid in patients suffering from idiopathic pulmonary fibrosis.
-
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
3/28/2024
Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that additional data from the ABACUS-1 trial has been accepted for presentation at the Association for Research in Vision
-
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
3/28/2024
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced it will host a webcast on Thursday, April 11, 2024, at 8:00 a.m. ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape.
-
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
3/28/2024
Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC) today announced that management will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium, being held on Tuesday, April 2, 2024 at 10:40 a.m. ET.
-
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
3/28/2024
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference.
-
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
3/28/2024
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time.
-
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
3/28/2024
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced that it will be presenting at two upcoming investor conferences in Denver and New York.
-
Moderna has entered into a development and commercialization funding agreement with asset management firm Blackstone Life Sciences to help advance its pipeline of flu vaccine candidates.
-
Global healthcare and life sciences look toward automation, AI and Quantum to protect patient data and save lives.
-
Coave Therapeutics to Present at Upcoming Conferences - March 27, 2024
3/27/2024
Coave Therapeutics, a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following upcoming investor and industry conferences.
-
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
3/27/2024
Jaguar Health, Inc. announced that the company will conduct an investor webcast on Monday, April 1, 2024 at 8:30 a.m. Eastern Standard Time to review fourth-quarter 2024 financials and provide corporate updates.
-
Aqtual to Present Poster at American Association for Cancer Research Annual Meeting 2024
3/27/2024
Aqtual, Inc. announced that it will present a poster at the American Association for Cancer Research Annual Meeting, held April 5-10, 2024, in San Diego, California.
-
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
3/27/2024
AXIM Biotechnologies, Inc. released a fireside chat interview conducted with its CEO John Huemoeller II and Tony Noto at the 2024 Benzinga Virtual Healthcare Summit.
-
Zymeworks Announces Participation in Upcoming April 2024 Investor Conferences
3/27/2024
Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced that management will participate in the following upcoming investor conferences.
-
Wave Life Sciences to Present at Upcoming April 2024 Investor Conferences
3/27/2024
Wave Life Sciences Ltd. announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in April.
-
Congruence Therapeutics to Present at Multiple Upcoming Investor Conferences - March 27, 2024
3/27/2024
Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function, announced that it will participate in the following investor conferences.
-
YolTech Therapeutics to Participate in 2024 Cell & Gene Meeting on the Mediterranean
3/27/2024
YolTech Therapeutics, a trailblazing biopharmaceutical company specializing in gene editing, is delighted to announce its participation in 2024 Cell & Gene Meeting on the Mediterranean.
-
Notice to Annual General Meeting in BioInvent International AB - March 27, 2024
3/27/2024
The shareholders of BioInvent International AB, Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 3 May 2024 at Elite Hotel Ideon on Scheelevägen 27 in Lund, Sweden.
-
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
3/27/2024
Moleculin Biotech, Inc. announced that it will present at the Virtual Investor Lunch Break: The Moleculin Opportunity event on Thursday, March 28, 2024 at 12:00 PM ET.